Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Stopped The planned enrollment was 130 patients and the study was halted prematurely due to lack of efficacy in both arms. Enrolled patients continued treatment.

Conditions

• Metastatic Pancreatic Cancer

Interventions

• BIOLOGICAL: cetuximab
• BIOLOGICAL: bevacizumab
• DRUG: gemcitabine
• BIOLOGICAL: cetuximab

Sponsor

Eli Lilly and Company